Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Meitav Investment House Ltd.

Meitav Investment House Ltd. lessened its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 81.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 42,860 shares of the company's stock after selling 184,043 shares during the quarter. Meitav Investment House Ltd.'s holdings in Moderna were worth $1,782,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its position in Moderna by 365.6% during the third quarter. Blue Trust Inc. now owns 731 shares of the company's stock valued at $49,000 after buying an additional 574 shares during the period. Wilmington Savings Fund Society FSB grew its position in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares during the period. Venturi Wealth Management LLC lifted its holdings in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares in the last quarter. Larson Financial Group LLC lifted its holdings in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company's stock valued at $61,000 after purchasing an additional 317 shares in the last quarter. Finally, Rakuten Securities Inc. lifted its holdings in Moderna by 477.3% during the third quarter. Rakuten Securities Inc. now owns 941 shares of the company's stock valued at $63,000 after purchasing an additional 778 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Insiders Place Their Bets

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 2,664 shares of company stock valued at $115,210 over the last ninety days. Company insiders own 15.70% of the company's stock.

Analyst Ratings Changes

MRNA has been the topic of several recent analyst reports. Argus downgraded shares of Moderna from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Barclays downgraded shares of Moderna from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $111.00 to $45.00 in a report on Tuesday. The Goldman Sachs Group downgraded shares of Moderna from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Bank of America decreased their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Finally, Evercore ISI decreased their price objective on shares of Moderna from $60.00 to $50.00 and set an "in-line" rating on the stock in a report on Monday, January 27th. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Moderna currently has an average rating of "Hold" and a consensus target price of $60.63.

Moderna Trading Up 5.3 %

MRNA stock traded up $1.80 during trading on Friday, reaching $35.53. 21,324,853 shares of the stock were exchanged, compared to its average volume of 13,159,273. The business has a 50 day moving average price of $38.17 and a 200-day moving average price of $53.20. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47. The firm has a market capitalization of $13.67 billion, a price-to-earnings ratio of -3.83 and a beta of 1.59.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.